Rexahn Pharmaceuticals Price / Sales Ratio
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
About Price to Sales Ratio
The price to sales ratio (PS ratio) is calculated by dividing stock price by the revenue per share. It is most useful for comparing companies within a sector or industry because "normal" values for this ratio vary from industry to industry. In general, low price to sales ratios are more appealing because they suggest that a company is undervalued.
An example illustrating why PS ratios should not be compared across industries: On June 21, 2010, Starbucks had a PS ratio of 1.12 while Yahoo! had a PS ratio of 2.56. In other words, Yahoo! shareholders were paying $2.56 for $1 of sales while Starbucks shareholders would only pay $1.12 for $1 of sales. However, at that same moment, the two companies' price to earnings ratios were virtually identical (Starbucks: 28.09 and Yahoo!: 27.78). Hence, shareholders were paying nearly the same amount for $1.00 in earnings. The PS ratios, though, are less comparable since Yahoo!'s profit margins are much higher than that of Starbucks.
Learn More
You may also be interested in these RNN related companies
RNN News
Rexahn Pharmaceuticals Publishes New Preclinical Data for Quinoxalinyl-Piperazine Compounds
Jan 25, 8:00AM Benzinga
Jan 25, 8:00AM Benzinga
Rodman & Renshaw Changes Rating on Rexahn Pharmaceuticals to Market Perform
Jan 18, 12:44PM Benzinga
Jan 18, 12:44PM Benzinga
Rexahn Pharmaceuticals (RNN) Receives Approval in Europe to Conduct a First-in-Human Trial of RX-3117
Jan 18, 8:03AM Street Insider
Jan 18, 8:03AM Street Insider
Drug Candidates From Rexahn and Elite Pharmaceuticals Look to Pass Key Tests
Nov 09, 8:16AM Marketwire
Nov 09, 8:16AM Marketwire
Rexahn Pharmaceuticals (RNN) Offers Results from Phase II Trial of Serdaxin for Major Depressive Disorder
Nov 04, 8:26AM Street Insider
Nov 04, 8:26AM Street Insider
Rexahn Pharmaceuticals Announces Phase II Results for Serdaxin® as Treatment for Major Depressive Disorder
Nov 04, 8:00AM Business Wire
Nov 04, 8:00AM Business Wire
Rexahn Pharmaceuticals granted U.S. patent for isoquinolinamine compounds
Oct 12, 8:01AM FlyOnTheWall
Oct 12, 8:01AM FlyOnTheWall
Rexahn Pharmaceuticals Granted US Patent for Novel Anti-cancer Isoquinolinamine Compounds
Oct 12, 8:00AM Business Wire
Oct 12, 8:00AM Business Wire
Rexahn Pharmaceuticals Announces Publication of Study Validating Mechanism of Action of Serdaxin®
Oct 03, 8:00AM Business Wire
Oct 03, 8:00AM Business Wire
Rexahn Pharmaceuticals to Present at the Rodman & Renshaw 13th Annual Healthcare Conference
Sep 08, 8:00AM Business Wire
Sep 08, 8:00AM Business Wire
Rexahn Pharmaceuticals announces patent for neurotherapeutic compositions
Aug 08, 9:03AM FlyOnTheWall
Aug 08, 9:03AM FlyOnTheWall
$RNN http://chart.ly/bxxaome Do not like the Company at all; however they have done some excellent P&D. very tight range.
about 198 days ago by Wiserguy1971
about 198 days ago by Wiserguy1971
sold the $RNN I've been holding for at least a month at 1.21 for small loss. don't like the large shelf offering
about 234 days ago by LitheLyricist
about 234 days ago by LitheLyricist
RT @ABtrader $RNN sees completing Trial, announcing Prelim Results before Yr End = Should see some big action today.
about 235 days ago by epollux
about 235 days ago by epollux
$rnn: RNN. Jeremy Richards posted on Seeking alpha " I will have a new article out soon on why RNN is a takeover target."'
about 237 days ago by goldmanwho
about 237 days ago by goldmanwho
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| RNN | 0.60 | -0.00 | -0.33% | 56.95M |
| FLR | 59.57 | -0.65 | -1.08% | 10.35B |
| GNW | 8.73 | -0.17 | -1.96% | 4.29B |
| PGI | 8.98 | -0.26 | -2.81% | 460.05M |
| C | 32.92 | -0.73 | -2.18% | 96.26B |
| GFI | 16.47 | -0.20 | -1.20% | 11.93B |
| BAC | 8.07 | -0.11 | -1.34% | 81.78B |
| AMT | 63.29 | -0.50 | -0.78% | 25.05B |
| UNP | 111.63 | -1.17 | -1.04% | 53.93B |
| FRP | 4.42 | -0.43 | -8.87% |
